Research programme: lysosomal acid lipase - Large Scale Biology Corporation

Drug Profile

Research programme: lysosomal acid lipase - Large Scale Biology Corporation

Latest Information Update: 20 Feb 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Cincinnati
  • Developer Large Scale Biology Corporation (CEASED)
  • Class Cardiovascular therapies
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Atherosclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 23 Dec 2005 Large Scale Biology Corporation ceased operations
  • 23 Sep 2005 Large Scale Biology Corporation and Icon Genetics announced the initiation of the commercial phase of their collaborative agreement for an undisclosed product for enzyme replacement therapy
  • 01 Aug 2005 Lysosomal acid lipase has received orphan drug status in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top